Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease

Publisher： Karger

E-ISSN： 2296-5262|39|9|548-552

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.9, 2016-08, pp. : 548-552

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

By  

CANCER, Vol. 121, Iss. 16, 2015-08 ,pp. : 2749-2756

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Evolving Use of Radioiodine Therapy in Differentiated Thyroid Cancer

By  

Oncology, Vol. 88, Iss. 4, 2014-12 ,pp. : 247-256

Karger

Access to resources Recommend Favorite

Effects of radioiodine treatment for differentiated thyroid cancer on testis function

By  

CLINICAL ENDOCRINOLOGY, Vol. 82, Iss. 2, 2015-02 ,pp. : 295-299

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-06 ,pp. : 393-400

Karger

Access to resources Recommend Favorite

Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital

By  

Current Medical Imaging Reviews, Vol. 6, Iss. 1, 2010-02 ,pp. : 2-7

Bentham Science Publishers

Access to resources Recommend Favorite